Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)

Hajek, R, Terpos, E, Lee, HC et al. (20 more authors) (2018) Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG). In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

Metadata

Authors/Creators:
  • Hajek, R
  • Terpos, E
  • Lee, HC
  • Chari, A
  • Costello, CL
  • Puig, N
  • Leleu, X
  • Berdeja, JG
  • Davies, FE
  • Weisel, K
  • Usmani, SZ
  • Hungria, VTM
  • Boccadoro, M
  • Rifkin, RM
  • Zonder, JA
  • Cook, G ORCID logo https://orcid.org/0000-0003-0223-3652
  • Brožová, L
  • Bařinová, M
  • Ren, K
  • Cacioppo, R
  • Skacel, T
  • Stull, DM
  • Maisnar, V
Dates:
  • Published: 29 November 2018
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 17 Feb 2020 11:26
Last Modified: 17 Feb 2020 11:54
Status: Published
Publisher: American Society of Hematology
Identification Number: https://doi.org/10.1182/blood-2018-99-113441
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)